Goldman Sachs’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-137,520
| Closed | -$2.26M | – | 6011 |
|
|
2023
Q4 | $2.26M | Buy |
+137,520
| New | +$2.17M | ﹤0.01% | 3824 |
|
|
2023
Q3 | – | Sell |
-28,364
| Closed | -$148K | – | 5973 |
|
|
2023
Q2 | $148K | Buy |
28,364
+52
| +0.2% | +$265 | ﹤0.01% | 5273 |
|
|
2023
Q1 | $152K | Buy |
28,312
+26,290
| +1,300% | +$143K | ﹤0.01% | 5380 |
|
|
2022
Q4 | $7.5K | Buy |
+2,022
| New | +$8.94K | ﹤0.01% | 5778 |
|
|
2022
Q2 | – | Sell |
-3,679
| Closed | -$26K | – | 6821 |
|
|
2022
Q1 | $26K | Sell |
3,679
-3,654
| -50% | -$35.8K | ﹤0.01% | 6379 |
|
|
2021
Q4 | $97K | Buy |
7,333
+4,199
| +134% | +$69.4K | ﹤0.01% | 6142 |
|
|
2021
Q3 | $72K | Buy |
3,134
+353
| +13% | +$10.5K | ﹤0.01% | 5974 |
|
|
2021
Q2 | $122K | Buy |
2,781
+487
| +21% | +$27.1K | ﹤0.01% | 5895 |
|
|
2021
Q1 | $167K | Sell |
2,294
-26,862
| -92% | -$1.91M | ﹤0.01% | 5703 |
|
|
2020
Q4 | $1.26M | Buy |
29,156
+23,323
| +400% | +$1.04M | ﹤0.01% | 4049 |
|
|
2020
Q3 | $240K | Sell |
5,833
-11,361
| -66% | -$587K | ﹤0.01% | 4844 |
|
|
2020
Q2 | $1.03M | Buy |
17,194
+11,122
| +183% | +$1.02M | ﹤0.01% | 3924 |
|
|
2020
Q1 | $457K | Buy |
6,072
+3,609
| +147% | +$416K | ﹤0.01% | 4268 |
|
|
2019
Q4 | $339K | Buy |
2,463
+1,059
| +75% | +$129K | ﹤0.01% | 4699 |
|
|
2019
Q3 | $167K | Buy |
+1,404
| New | +$196K | ﹤0.01% | 4865 |
|
Goldman Sachs's ORTX Position: Q1 2024 in Review
Goldman Sachs sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 137,520 shares — an estimated $2.26M sold.
Goldman Sachs first reported a position in ORTX in Q3 2019 and held it in 15 quarters. The position peaked at $2.26M in Q4 2023. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.
- Goldman Sachs reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
- Goldman Sachs sold 137,520 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $2.26M.
- Goldman Sachs first reported a position in Orchard Therapeutics plc American Depositary Shares in Q3 2019 and held it in 15 quarters.
- Goldman Sachs's Orchard Therapeutics plc American Depositary Shares position peaked at $2.26M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.
Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.